ABECMA Trademark

Trademark Overview

On Wednesday, November 21, 2018, a trademark application was filed for ABECMA with the United States Patent and Trademark Office. The USPTO has given the ABECMA trademark a serial number of 88202247. The federal status of this trademark filing is REGISTERED as of Tuesday, January 14, 2020. This trademark is owned by Celgene Corporation. The ABECMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the treatment of multiple myeloma, blood disease, cancer, diseases in the fields of oncology, immunology and inflammation; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system
abecma

General Information

Serial Number88202247
Word MarkABECMA
Filing DateWednesday, November 21, 2018
Status700 - REGISTERED
Status DateTuesday, January 14, 2020
Registration Number5958800
Registration DateTuesday, January 14, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 29, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in the treatment of multiple myeloma, blood disease, cancer, diseases in the fields of oncology, immunology and inflammation; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 11, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Friday, December 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, December 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 9, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, December 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, December 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, December 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, January 14, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, October 29, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 29, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 9, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, September 19, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 16, 2019EXAMINER'S AMENDMENT ENTERED
Monday, September 16, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, September 16, 2019EXAMINERS AMENDMENT E-MAILED
Monday, September 16, 2019EXAMINERS AMENDMENT -WRITTEN
Thursday, September 5, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 5, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 3, 2019ASSIGNED TO LIE
Thursday, August 22, 2019ASSIGNED TO LIE
Wednesday, August 14, 2019TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, February 26, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, February 26, 2019LETTER OF SUSPENSION E-MAILED
Tuesday, February 26, 2019SUSPENSION LETTER WRITTEN
Monday, February 25, 2019ASSIGNED TO EXAMINER
Friday, February 22, 2019TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, December 11, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, November 24, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

abecma pharmaceutical preparations namely cytokine inflammation inhibitory drugs system immune modulate